Your browser doesn't support javascript.
loading
Single enzyme nanoparticle, an effective tool for enzyme replacement therapy.
Kim, Dong Hyun; Lee, Han Sol; Kwon, Tae-Wan; Han, Young-Min; Kang, Nae-Won; Lee, Mee Yeon; Kim, Dae-Duk; Kim, Myeong Gyu; Lee, Jae-Young.
Afiliação
  • Kim DH; College of Pharmacy, Chungnam National University, Daejeon, 34134, Republic of Korea.
  • Lee HS; College of Pharmacy, Chungnam National University, Daejeon, 34134, Republic of Korea.
  • Kwon TW; College of Pharmacy, Chungnam National University, Daejeon, 34134, Republic of Korea.
  • Han YM; College of Pharmacy, Chungnam National University, Daejeon, 34134, Republic of Korea.
  • Kang NW; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 08826, Republic of Korea.
  • Lee MY; Department of Pharmacy, Seoul National University Seoul Metropolitan Government Boramae Medical Center, Seoul, 07610, Republic of Korea.
  • Kim DD; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 08826, Republic of Korea.
  • Kim MG; Graduate School of Clinical Pharmacy, CHA University, Pocheon, 11160, Republic of Korea. kimmg@cha.ac.kr.
  • Lee JY; College of Pharmacy, Chungnam National University, Daejeon, 34134, Republic of Korea. jaeyoung@cnu.ac.kr.
Arch Pharm Res ; 43(1): 1-21, 2020 Jan.
Article em En | MEDLINE | ID: mdl-31989476
ABSTRACT
The term "single enzyme nanoparticle" (SEN) refers to a chemically or biologically engineered single enzyme molecule. SENs are distinguished from conventional protein nanoparticles in that they can maintain their individual structure and enzymatic activity following modification. Furthermore, SENs exhibit enhanced properties as biopharmaceuticals, such as reduced antigenicity, and increased stability and targetability, which are attributed to the introduction of specific moieties, such as poly(ethylene glycol), carbohydrates, and antibodies. Enzyme replacement therapy (ERT) is a crucial therapeutic option for controlling enzyme-deficiency-related disorders. However, the unfavorable properties of enzymes, including immunogenicity, lack of targetability, and instability, can undermine the clinical significance of ERT. As shown in the cases of Adagen®, Revcovi®, Palynziq®, and Strensiq®, SEN can be an effective technology for overcoming these obstacles. Based on these four licensed products, we expect that additional SENs will be introduced for ERT in the near future. In this article, we review the concepts and features of SENs, as well as their preparation methods. Additionally, we summarize different types of enzyme deficiency disorders and the corresponding therapeutic enzymes. Finally, we focus on the current status of SENs in ERT by reviewing FDA-approved products.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fenilalanina Amônia-Liase / Proteínas Recombinantes de Fusão / Proteínas Recombinantes / Imunoglobulina G / Adenosina Desaminase / Fosfatase Alcalina / Nanopartículas / Terapia de Reposição de Enzimas Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fenilalanina Amônia-Liase / Proteínas Recombinantes de Fusão / Proteínas Recombinantes / Imunoglobulina G / Adenosina Desaminase / Fosfatase Alcalina / Nanopartículas / Terapia de Reposição de Enzimas Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article